Compare PBF & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBF | TNGX |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.1B |
| IPO Year | 2011 | 2020 |
| Metric | PBF | TNGX |
|---|---|---|
| Price | $52.75 | $30.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $36.25 | $21.78 |
| AVG Volume (30 Days) | 2.6M | ★ 4.8M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | ★ 69.78 | 26.89 |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $24,508,200,000.00 | $62,384,000.00 |
| Revenue This Year | $8.77 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.23 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $21.24 | $5.60 |
| 52 Week High | $54.82 | $34.39 |
| Indicator | PBF | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 71.04 | 57.19 |
| Support Level | $36.97 | $28.13 |
| Resistance Level | N/A | $33.96 |
| Average True Range (ATR) | 2.56 | 1.82 |
| MACD | 1.14 | -0.24 |
| Stochastic Oscillator | 88.72 | 53.06 |
PBF Energy Inc is an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants, and other petroleum products in the United States. The company owns refineries in Delaware, Ohio, New Jersey, California, and Louisiana. The Company operates in two reportable business segments: Refining and Logistics. The Company's oil refineries are all engaged in the refining of crude oil and other feedstocks into petroleum products and are aggregated into the Refining segment. PBFX operates logistics assets such as crude oil and refined products terminals, pipelines, and storage facilities. The Logistics segment consists solely of PBFX's operations.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.